|Table of Contents|

Research progress of small molecule anti-angiogenic drugs in non-small cell lung cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 04
Page:
663-667
Research Field:
Publishing date:

Info

Title:
Research progress of small molecule anti-angiogenic drugs in non-small cell lung cancer
Author(s):
Liu Liya; Zhu Ying; Tu Changling; Jiang Bo
Cadre Medical Department,the Third Affiliated Hospital of Kunming Medical University,Yunnan Kunming 650118,China.
Keywords:
advanced non-small cell lung cancer; small molecule antiangiogenic drugs; research progress; review
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2020.04.033
Abstract:
The morbidity and mortality of lung cancer is the world's most of malignant tumor.Currently the main therapies for advanced non-small cell lung cancer methods have chemotherapy treatment，targeted treatment,immunotherapy treatment,anti-angiogenesis therapy and radiotherapy treatment.New blood vessels not only can promote the growth of tumor formation,but also to assist the transfer.Therefore,at present,anti-angiogenic drug therapy has become a research hotspot in advanced lung cancer,and VEGFR is a key factor in inducing angiogenesis.It is overexpressed in a variety of tumors including lung cancer,and inhibiting VEGFR can not only normalize tumor blood vessels,but also inhibit angiogenesis,thus playing a better role.VEGF inhibitors include anti-VEGF antibodies,soluble VEGFR,anti-VEGF receptor antibodies,small molecule tyrosine kinase inhibitors (TKIs).At present,the small-molecule drugs mainly used in the research of advanced non-small cell lung cancer include anlotinib,apatinib,furquinitinib,nidanibab and famitinib,and studies have shown that the combination of anti-angiogenic drugs with chemotherapy,targeted drugs,immunosuppressive drugs and other drugs can enhance the therapeutic effect.Therefore,this paper mainly reviews the theoretical basis of the mechanism of action of anti-angiogenic drugs in combination with other drugs and the research progress of small-molecule anti-angiogenic drugs in advanced non-small cell lung cancer.

References:

［1］Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2018,68(6):394-424.
［2］Ettinger DS,Akerley W,Borghaei H,et al.Non-small cell lung cancer,version 2.2013［J］.J Natl Compr Canc Netw,2013,11(6):645-653.
［3］Folkman J.Tumor angiogenesis:Therapeutic implications［J］.N Engl J Med,1971,285(21):1182.
［4］ZHOU CC,WU YL,FEI K,et al.Angiogenesis mechanism and treatment of lung cancer,biological targeted therapy for lung cancer［M］.Beijing:People's Health Publishing House,2016:189.［周彩存，吴一龙,费苛,等.肺癌血管生成机制及治疗,肺癌生物靶向治疗［M］.北京：人民卫生出版社，2016:189.］
［5］ZHANG MZ,CHEN JW,HU J,et al.Progress in the mechanism of action of anti-angiogenic drugs［J］.Chinese Journal of Pharmacology and Toxicology,2016，30(10):1120-1124.［张梦泽,陈锦文,胡健,等.抗血管生成药物作用机制研究进展［J］.中国药理学与毒理学杂志,2016,30(10):1120-1124.］
［6］Liang YZ,Zeng ZL,Hua LL,et al.Expression and significance of angiostatin,vascular endothelial growth factor and matrix metalloproteinase-9 in brain tissue of diabetic rats with ischemia reperfusion［J］.Asian Pac J Trop Med,2016,9(6):587-591.
［7］SHANG LQ,ZHAO J,WANG W,et al.Inhibition of recombinant human vascular endostatin on lymphangiogenesis in non-small cell lung cancer and its effect on circulating tumor cells［J］.Chinese Journal of Lung Cancer,2014,17(10):722-729.［尚立群,赵皆,王伟,等.重组人血管内皮抑素对非小细胞肺癌淋巴管生成的抑制及对循环肿瘤细胞的影响［J］.中国肺癌杂志,2014,17(10):722-729.］
［8］Persson C,Sjoblom T,Groen A,et al.Preferential oxidation of the second phosphatase domain of receptor-like PTP-alpha revealed by an antibody against oxidized protein tyrosine phosphatases［J］.Proc Natl Acad Sci USA,2004,101(7):1886-1891.
［9］Hojjat-Farsangi M.Small-molecule inhibitors of the receptor tyrosine kinases:Promising tools for targeted cancer therapies［J］.Int J Mol Sci,2014,15(8):13768-13801.
［10］Hubbard SR,Miller WT.Receptor tyrosine kinases:Mechanisms of activation and signaling［J］.Current Opinion in Cell Biology,2007,19(2):117-123.
［11］LU MY,ZHONG WL,SI CF,et al.Progress of tumor angiogenesis mechanism and targeted drugs against tumor angiogenesis［J］.Anhui Pharmaceutical,2018,22(05):798-802.［鲁美钰,仲维兰,司春枫,等.肿瘤血管生成机制及抗肿瘤血管新生的靶向药物研究进展［J］.安徽医药,2018,22(05):798-802.］
［12］Folkman J.Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action［J］.Exp Cell Res,2006,312(5):594-607.
［13］Pouyssegur J,Dayan F,Mazure NM.Hypoxia signalling in cancer and approaches to enforce tumour regression［J］.Nature,2006,441(7092):437-443.
［14］Byers LA,Heymach JV.Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways:Rationale and clinical applications for non-small-cell lung cancer［J］.Clin Lung Cancer,2007,8(Suppl 2):S79-S85.
［15］Tonra JR,Deevi DS,Corcoran E,et al.Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy［J］.Clin Cancer Res,2006,12(7 Pt 1):2197-2207.
［16］Huang Y,Goel S,Duda DG,et al.Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles［J］.ACS Nano,2015,9(9):8689-8696.
［17］Taylor CT,Colgan SP.Regulation of immunity and inflammation by hypoxia in immunological niches［J］.Nat Rev Immunol,2017,17(12):774-785.
［18］Huang Y,Yuan J,Righi E,et al.Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy［J］.Proc Natl Acad Sci USA,2012,109(43):17561-17566.
［19］Shrimali RK,Yu Z,Theoret MR,et al.Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer［J］.Cancer Res,2010,70(15):6171-6180.
［20］Jiang W,Huang Y,An Y,et al.Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles［J］.ACS Nano,2015,9(9):8689-8696.
［21］Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRbeta and FGFR1［J］.Gene,2018(654):77-86.
［22］Han B,Li K,Zhao Y,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small cell lung cancer:A multicentre,randomised phase II trial (ALTER0302)［J］.Br J Cancer,2018,118(5):654-661.
［23］Han B,Li K,Wang Q,et al.Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer:The ALTER 0303 phase 3 randomized clinical trial［J］.JAMA Oncol,2018,4(11):1569-1575.
［24］Si X,Zhang L,Wang H,et al.Quality of life results from a randomized,double-blinded,placebo-controlled,multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer［J］.Lung Cancer,2018(122):32-37.
［25］Zeng DX,Wang CG,Huang JA,et al.Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation［J］.Onco Targets Ther,2017(10):4269-4272.
［26］Chen Y,Ma G,Su C,et al.Apatinib reverses alectinib resistance by targeting vascular endothelial growth factor receptor 2 and attenuating the oncogenic signaling pathway in echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene-positive lung cancer cell lines［J］.Anticancer Drugs,2018,29(10):935-943.
［27］Li F,Zhu T,Cao B,et al.Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance［J］.Eur J Cancer,2017(84):184-192.
［28］Wu F,Zhang S,Xiong A,et al.A phase II clinical trial of apatinib in pretreated advanced non-squamous non-small cell lung cancer［J］.Clinical Lung Cancer,2018,19(6):e831-e842.
［29］Liu Z,Ou W,Li N,et al.Apatinib monotherapy for advanced non-small cell lung cancer after the failure of chemotherapy or other targeted therapy［J］.Thorac Cancer,2018,9(10):1285-1290.
［30］Xu J,Liu X,Yang S,et al.Clinical response to apatinib monotherapy in advanced non-small cell lung cancer［J］.Asia Pac J Clin Oncol,2018,14(3):264-269.
［31］Zeng DX,Wang CG,Huang JA,et al.Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation［J］.Onco Targets Ther,2017(10):4269-4272.
［32］Fang S,Zhang M,Wei G,et al.Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR［J］.Oncotarget,2018,6(9):7175-7181.
［33］Fan S,Zou Y,Wang Y,et al.An observational study of apatinib mesylate in treating advanced non-small cell lung cancer with unknown driving genes［J］.J BUON,2018,23(3):654-658.
［34］Fang SC,Zhang HT,Zhang YM,et al.Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma［J］.Onco Targets Ther,2017(10):447-452.
［35］WANG XM,ZHANG WH,DU WJ,et al.Efficacy and survival analysis of Apatinib for advanced non-squamous non-small cell lung cancer after the progress of first-line treatment［J］.Chinese Journal of Lung Cancer,2017，20(11):761-768.［王学敏,张维红,杜伟娇,等.阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析［J］.中国肺癌杂志,2017,20(11):761-768.］
［36］LIU XY,ZHENG J.Apatinib combined with docetaxel second-line chemotherapy in the treatment of advanced non-squamous non-small cell lung cancer［J］.Journal of Practical Cardio-Cerebrovascular Diseases,2018，26(06):104-107.
［刘旭阳,郑静.阿帕替尼联合多西他赛二线化疗治疗晚期非鳞非小细胞肺癌的疗效观察［J］.实用心脑肺血管病杂志,2018,26(06):104-107.］
［37］XU SJ.Observation of the efficacy and adverse reactions of apatinib mesylate combined with sergio in the treatment of advanced non-small cell lung cancer［J］.Famous Doctor,2018(09):233.［徐绍君.观察甲磺酸阿帕替尼联合替吉奥治疗晚期非小细胞肺癌的疗效及不良反应［J］.名医,2018(09):233.］
［38］Xu J,Liu X,Yang S,et al.Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure:A retrospective study［J］.Onco Targets Ther,2017(10):4989-4995.
［39］Sun Q,Zhou J,Zhang Z,et al.Discovery of fruquintinib,a potent and highly selective small molecule inhibitor of VEGFR 1,2,3 tyrosine kinases for cancer therapy［J］.Cancer Biol Ther,2014,15(12):1635-1645.
［40］Cao J,Zhang J,Peng W,et al.A phase I study of safety and pharmacokinetics of fruquintinib,a novel selective inhibitor of vascular endothelial growth factor receptor-1,-2,and -3 tyrosine kinases in Chinese patients with advanced solid tumors［J］.Cancer Chemother Pharmacol,2016,78(2):259-269.
［41］Lu S,Chang J,Liu X,et al.Randomized,double-blind,placebo-controlled,multicenter phase II study of fruquintinib after two prior chemotherapy regimens in Chinese patients with advanced non-squamous non-small cell lung cancer［J］.J Clinical Oncology,2018,36(12):1207-1217.
［42］Reck M,Kaiser R,Mellemgaard A,et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small cell lung cancer (LUME-Lung 1):A phase 3,double-blind,randomised controlled trial［J］.Lancet Oncol,2014,15(2):143-155.
［43］Hanna NH,Kaiser R,Sullivan RN,et al.Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory,advanced non-small cell lung cancer (LUME-Lung 2):A randomized,double-blind,phase III trial［J］.Lung Cancer,2016(102):65-73.

Memo

Memo:
医学科学研究基金资助项目（编号：YWJKJJHKYJJ-F3167D）
Last Update: 2019-12-26